Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer?
{{output}}
The investigators of the recent phase III SPIRITS trial found that the addition of cisplatin to S-1 (a fourth generation oral fluoropyrimidine) provided a significant overall survival advantage (P = 0.04) over treatment with S-1 alone among previously untreate... ...
